Medicamen Biotech valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
31.84×————
1.25×————
1.70×————
Enterprise multiples
1.78×————
18.73×————
29.88×————
Yield
3.1%————
−11.0%————
Reference — adjusted share basis
₹254.25————
₹7.98₹7.11₹5.24₹8.06₹10.94
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MEDICAMEQ₹254.25

Medicamen Biotech Limited

· Pharma & Health
₹ CrorePeersMEDICOAAREYDRUGSNECLIFEHALEOSLABSALBERTDAVDNATCAPSUQVALIANTLABBALPHARMAMcap ₹345 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————31.84
P/B————1.25
P/Sales————1.70
Enterprise Multiples
EV/Sales————1.78
EV/EBITDA————18.73
EV/EBIT————29.88
Yield
Earnings Yield %————3.14
FCF Yield %————-11.01
Reference — adjusted share basis
Price (FY-end close, adj.)————254.25
EPS (adj.)10.948.065.247.117.98
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.